Last reviewed · How we verify
APOTEL max
APOTEL max is a fixed-dose combination of paracetamol (acetaminophen) and an additional analgesic or anti-inflammatory agent that works to reduce pain and fever through multiple pathways.
APOTEL max is a fixed-dose combination of paracetamol (acetaminophen) and an additional analgesic or anti-inflammatory agent that works to reduce pain and fever through multiple pathways. Used for Mild to moderate pain, Fever reduction.
At a glance
| Generic name | APOTEL max |
|---|---|
| Also known as | Paracetamol solution for infusion, 1gram per 100ml bag |
| Sponsor | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. |
| Drug class | Analgesic combination |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
APOTEL max typically combines paracetamol with another active ingredient (likely a non-steroidal anti-inflammatory drug or additional analgesic) to provide enhanced pain relief and fever reduction. Paracetamol acts as a cyclooxygenase inhibitor in the central nervous system, while co-formulated agents may provide peripheral anti-inflammatory effects, resulting in synergistic analgesic and antipyretic activity.
Approved indications
- Mild to moderate pain
- Fever reduction
Common side effects
- Gastrointestinal upset
- Nausea
- Hepatotoxicity (at high doses)
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APOTEL max CI brief — competitive landscape report
- APOTEL max updates RSS · CI watch RSS
- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. portfolio CI